Latest by Barbara Jungwirth

This Week in HIV Research: Where Are the Cervical Cancer Screens?

Poor rates of cervical cancer screening for women of color; interest vs. action among potential organ donors; an online depression intervention; Truvada levels in men’s vs. women’s hair.

By Barbara Jungwirth and Myles Helfand

Medicines Patent Pool Model May Expand Beyond HIV Medications

The Medicines Patent Pool, which negotiates licenses with the manufacturers of new drugs that allow other companies to produce generic versions for distribution in low- and middle-income countries, is looking to expand beyond HIV drugs to medications...

By Barbara Jungwirth

This Week in HIV Research: Gendered Nuances in Care and Complications

Alcohol use worsens HIV care outcomes; sex-based differences in cognitive performance seen; higher cardiovascular risk among trans women; glycemic status related to cognitive function.

By Barbara Jungwirth and Myles Helfand

Public Health Approach = Do the Best for the Most People Using Resources Efficiently

While almost 60% of people living with HIV globally are on treatment, the numbers for new seroconversions averted and HIV-related deaths are no longer improving.

By Barbara Jungwirth

HIV Stigma Still Common in Europe, Survey Finds

In a recent survey of people not living with HIV, many still believed that people living with HIV should not be allowed to work in hospitals, restaurants, or universities, among other occupations, and 68% said they would be uncomfortable dating someo...

By Barbara Jungwirth

More People With HIV Virally Suppressed on Doravirine Than Darunavir at 96 Weeks, Study Shows

After 96 weeks, more people achieved viral suppression on a doravirine-based antiretroviral drug regimen compared with a darunavir (Prezista)-based one, according to data presented at the recent 22nd International AIDS Conference.

By Barbara Jungwirth

This Week in HIV Research: Treatment Does a Body Good

Early treatment reduces health risks; on-demand PrEP more popular than daily pill among French MSM; long-acting injectable PrEP preferred over daily pill in Swaziland; HIV-positive MSM aren’t testing for syphilis enough.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Another Notch in the 'Treatment as Prevention' Belt

“Opposites Attract” study piles on more data backing U=U; mixed results on enhanced HIV interventions among African sex workers; the tipping point for re-engagement in HIV care; thyroid function in the modern treatment era.

By Barbara Jungwirth and Myles Helfand

Dolutegravir-Based Two-Drug Regimen Just as Good for HIV Treatment as Three-Drug Therapy, Study Says

A dolutegravir-based two-drug regimen was non-inferior to the standard three-drug therapy among treatment-naive participants, according to results from the two GEMINI trials presented at the International AIDS Conference in Amsterdam, the Netherlands...

By Barbara Jungwirth

This Week in HIV Research: Mitigating an ICE-y Reception

HIV ramifications of the Trump administration’s anti-immigration efforts; HIV in plasma vs. rectal tissue; how HCV treatment affects HIV/HCV coinfection; HPV vaccination efficacy among women with HIV.

By Barbara Jungwirth and Myles Helfand